Recurrences during the chemoprophylactic treatment of superficial tumors of the bladder.
A total of 88 patients who underwent resection for superficial stages Ta and T1 bladder tumors received chemoprophylactic treatment to prevent recurrence postoperatively. The first 44 patients were given doxorubicin at monthly intervals and the second 44 received doxorubicin plus mitomycin C alternately, with the first 6 instillations at weekly intervals and the rest monthly beginning 1 month after resection. Recurrences during treatment were assessed as an index of drug resistance. Tumor developed while the patients were undergoing treatment (9 to 10 months) in 15.9 per cent (7 of 44) of group 1 patients, 18.1 per cent (8 of 44) of group 2 patients and 17.0 per cent (15 of 88) of the total patients studied. At the initial post-treatment cystoscopy 12 to 16 months later 2 more patients in group 1 and none in group 2 had recognizable tumors. Treatment was continued in patients with recurrences. A total of 41 recurrences in 435 months of followup was recorded, for a rate of 9.42 recurrences per 100 patient-months. No worsening of the histological grading was noted but 2 patients with initial stage T1 disease had subsequent carcinoma in situ.
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002291:Carcinoma, Papillary / Q000188:drug therapy*; D004317:Doxorubicin / Q000627:therapeutic use; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D008937:Mitomycins / Q000627:therapeutic use; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy* / Q000517:prevention & control; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy*
D008937:Mitomycins; D004317:Doxorubicin